Results 1 to 10 of about 3,328,268 (306)
Fibrinolytic agents for peripheral arterial occlusion. [PDF]
Cochrane Database Syst Rev, 2013 Peripheral arterial thrombolysis is used in the management of peripheral arterial ischaemia. Streptokinase was originally used but safety concerns led to a search for other agents. Urokinase and recombinant tissue plasminogen activator (rt-PA) have increasingly become established as first line agents for peripheral arterial thrombolysis.
Robertson I, Kessel DO, Berridge DC.
europepmc +7 more sources
Novel Treatment of Staphylococcus aureus Device-Related Infections Using Fibrinolytic Agents. [PDF]
Antimicrob Agents Chemother, 2018 Hogan S, O'Gara JP, O'Neill E.
europepmc +4 more sources
The Use of Fibrinolytic Agents in the Salvage of Free Flaps: A Systematic Review. [PDF]
J Pers MedBackground: Microvascular thrombosis following free tissue transfer presents a complex challenge for surgeons and carries the potential risk of flap failure. The application of fibrinolytic agents represents a robust therapeutic option.
Mandal P +8 more
europepmc +2 more sources
Acta Scientiarum: Technology, 2022 Failure of hemostasis and the formation of blood clots in the arteries are the main reasons that provoke the onset of cardiovascular diseases (CVDs) such as myocardial infarction and ischemic stroke.
Ali Nawaz +6 more
doaj +3 more sources
Fibrin and Fibrinolytic Enzyme Cascade in Thrombosis: Unravelling the Role
Life, 2023 Blood clot formation in blood vessels (thrombosis) is a major cause of life-threatening cardiovascular diseases. These clots are formed by αA-, βB-, and ϒ-peptide chains of fibrinogen joined together by isopeptide bonds with the help of blood coagulation
Rajni Singh +3 more
doaj +2 more sources
Prospects of fibrinolytic proteases of bacteria from sea cucumber fermentation products as antithrombotic agent [PDF]
BIO Web of Conferences, 2020 Cardiovascular disease is among the largest contributors of premature mortality in the world caused by inflammation of blood vessels. The abnormalities provoke thrombus formation or thrombosis blocking blood vessels leading to strokes, heart attacks and ...
Fuad Hayatun +9 more
doaj +2 more sources
Combining antithrombotic and fibrinolytic agents: can it be done? [PDF]
Stroke, 2013 More than half of ischemic stroke patients who are treated with IV recombinant tissue-type plasminogen activator (rtPA) remain disabled at 3 months.1,2 The reasons are many. The IV rtPA rate of recanalizing occluded arteries is not as high as we would like, especially for large arterial occlusions, which are opened only 30% to 40% of the time.3–6 When ...
Khatri P, Mono ML.
europepmc +4 more sources
Türk Kardiyoloji Derneği Arşivi, 2020 Objective: Myocardial infarction is a leading cause of morbidity and mortality. Fibrinolytic administration is still a life-saving choice in ST-segment elevated myocardial infarction (STEMI), but the rate of successful reperfusion can be inconsistent ...
Ali Çoner +4 more
doaj +2 more sources
Indonesian Journal of Medical Laboratory Science and TechnologyThrombotic disorders are one of the leading causes of death in cardiovascular patients and contribute to the incidence of non-infectious diseases. The search for new anticoagulant agents to overcome the limitations associated with existing anticoagulant
Muhammad Ardi Afriansyah +2 more
doaj +3 more sources
Myocardial rupture after percutaneous coronary intervention of an unstable RCA lesion in myocardial infarction and concomitant stroke treated with intravenous fibrinolytic agents: A case report. [PDF]
Clin Case Rep, 2021 Bay B +4 more
europepmc +2 more sources